Shots:
Rallybio has entered into a definitive agreement to acquire Avenzo through a merger transaction, after which the combined company will operate under the name Avenzo Therapeutics & is expected to trade on Nasdaq under the ticker symbol "AVZO"
As per the deal, Avenzo shareholders will receive newly issued Rallybio shares based on the companies’…
Shots:
Servier has entered into an agreement with Edgewise Therapeutics to acquire its muscular dystrophy business, supporting Servier’s strategic ambition in rare neurology
As per the deal, Servier will acquire the muscular dystrophy business for ~$2.65B, incl. $1.55B upfront and ~$1.1B in regulatory & commercial milestone payments; closing is expected in Q3’26
The acquisition adds Edgewise’s…
Shots:
Eli Lilly will acquire 3 companies, Curevo, LimmaTech Biologics, & Vaccine Company, to build its infectious disease portfolio through differentiated vaccine & platform technologies
The deals incl. Curevo’s P-II shingles vaccine candidate amezosvatein, LimmaTech’s P-I vaccine LTB-SA7 targeting S. aureus infections, & Vaccine Company’s preclinical EBV vaccine platform leveraging proprietary in vivo nanoparticle technology
As…
Shots:
Olympus has entered into a definitive agreement to acquire BioProtect, incl. its Balloon Spacer system designed to protect healthy tissue during prostate cancer radiotherapy
As per the agreement, Olympus will acquire BioProtect in a deal valued at ~$270M, with certain amounts held in escrow subject to uninterrupted business operations; closing is expected by the…
Shots:
A consortium led by CVC and GBL launched a voluntary cash tender offer to acquire Recordati at €51.29/share, valuing the transaction at ~€10.7B (~$12.4B). The offer aims to delist Recordati from Euronext Milan & is expected to close in Q4’26
The offer is backed by Rossini, which agreed to tender its 97.9M shares (~46.8%…
Shots:
Medtronic has announced its intent to acquire SPR Therapeutics for an upfront payment of ~$650M, aiming to expand its neuromodulation portfolio with temporary peripheral nerve stimulation (PNS) tech for chronic pain management
Acquisition will add SPR’s FDA-cleared SPRINT PNS System to Medtronic’s pain management portfolio, which showed over 71% pts experienced significant pain relief…
Shots:
Assertio Holdings’ Board has approved a definitive agreement with Zydus Worldwide DMCC, a subsidiary of Zydus, to acquire all outstanding Assertio shares, delisting it from the Nasdaq
Assertio’s Board determined Zydus’ proposal constituted a “Superior Proposal” under the Garda merger agreement & authorized termination of the Garda transaction
As per the deal, Zydus will…
Shots:
Roche has entered into a definitive merger agreement to acquire PathAI, building on their 2021 partnership, which scaled up in 2024 to incl. the development of AI-enabled companion diagnostic algorithms
As per the deal, Roche will acquire PathAI for $750M upfront & ~$300M in additional milestone payments; closing is expected in H2’26
The acquisition…
Shots:
Angelini Pharma has entered into a definitive agreement to acquire all outstanding shares of Catalyst, marking Angelini’s entry into the US market
As per the deal, Angelini will acquire Catalyst for $31.5 per share in cash, for a total equity value of ~$4.1B; closing is expected in Q3’26
The acquisition will strengthen Angelini’s Brain Health…
Shots:
Bayer has entered into an agreement to fully acquire Perfuse Therapeutics, incl. its asset PER-001, complementing Bayer’s pipeline & expertise in ophthalmology
As per the deal, Bayer will acquire Perfuse for ~$2.45B, incl. $300M upfront payment & additional development, regulatory, & commercial milestone payments;
PER-001 (intravitreal implant), a small molecule endothelin receptor antagonist, is…

